Skip to main content
Gland Pharma Limited logo

Gland Pharma Limited — Investor Relations & Filings

Ticker · GLAND ISIN · INE068V01023 LEI · 335800JJVDY5R6KF5K34 BSE.NS Manufacturing
Open in API
Filings indexed 676 across all filing types
Latest filing 2026-01-29 Board/Management Inform…
Country IN India
Listing BSE.NS GLAND

About Gland Pharma Limited

https://glandpharma.com

Gland Pharma Limited is a specialized Contract Development and Manufacturing Organization (CDMO) focused on injectable formulations. The company operates primarily through a business-to-business (B2B) model, providing development and manufacturing services for a diverse range of sterile injectables. Its portfolio encompasses complex generics across various therapeutic areas, including oncology, ophthalmology, anti-infectives, and orthopedics. Gland Pharma maintains a vertically integrated supply chain, ensuring control over critical raw materials and active pharmaceutical ingredients. The company serves a global market, with a significant presence in regulated regions such as the United States, Europe, Canada, and Australia. Its manufacturing facilities adhere to international quality standards and hold approvals from major regulatory bodies. Key strengths include expertise in niche segments like heparin and enoxaparin, alongside a robust pipeline of complex delivery systems.

Recent filings

Filing Released Lang Actions
Change in Management
Board/Management Information Classification · 100% confidence The document is a formal notification addressed to stock exchanges regarding a change in senior management personnel, specifically the retirement of the Chief Operating Officer effective March 31, 2026. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulation 30, which pertains to disclosures about changes in management. The content includes details about the individual retiring and the effective date, but does not contain financial data, audit information, or any report content. The document is clearly an announcement of a management change rather than a financial report or other filing type.
2026-01-29 English
Copy of Newspaper Publication
Report Publication Announcement Classification · 85% confidence The document is a formal letter to the stock exchanges under SEBI Listing Regulations notifying them that newspaper advertisements for the Company’s unaudited Q3FY26 financial results have been published and enclosing copies. It does not itself present the full financial statements or substantive analysis, but rather announces the publication of the results (and points to where the full numbers and review reports can be accessed). This fits the “Report Publication Announcement” category rather than an actual Interim/Quarterly Report or Earnings Release.
2026-01-29 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 70% confidence The document is a letter addressed to stock exchanges regarding the earnings call recording for the quarter and nine months ended December 31, 2025. It states that the audio recording of the earnings call has been uploaded on the company's website and provides a weblink. The document does not contain the transcript or detailed financial results but is an announcement about the availability of the earnings call recording. The document length is short (1435 characters), and it serves as a notification rather than the actual earnings release or call transcript. Therefore, it fits best under the category of Call Transcript (CT) as it relates to the earnings call, but since it only announces the recording availability and does not provide the transcript text, the closest appropriate classification is Call Transcript (CT) with moderate confidence.
2026-01-28 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is titled 'Investor Presentation on Q3FY26 Financial Results' and is addressed to stock exchanges pursuant to SEBI regulations, indicating it is an official investor communication. It contains detailed financial highlights for Q3 and 9M FY26, including consolidated and segment-wise P&L data, margins, and other financial metrics. The presence of forward-looking statements and disclaimers typical of investor presentations further supports this classification. The document length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or summary. Therefore, it is not a report publication announcement or a regulatory filing. The content aligns with the definition of an Investor Presentation (IP), which focuses on financials, strategy, and market position for investors.
2026-01-28 English
Press Release
Interim / Quarterly Report Classification · 95% confidence The document is a press release dated January 28, 2026, announcing the Q3 FY26 financial results of Gland Pharma Limited. It includes detailed quarterly and nine-month financial performance data, such as revenue, EBITDA, PAT, and segment-wise performance. The document also contains management commentary on the results and business highlights like R&D expenses, new product launches, and filings. The presence of comprehensive financial data and analysis for a quarter (Q3 FY26) indicates this is a quarterly financial report rather than a brief earnings announcement or a simple notification. The document is about 15,000 characters long, which is substantial and consistent with a detailed interim/quarterly report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2026
2026-01-28 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 82% confidence The document is the formal announcement of the Board meeting outcome where the Board approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, accompanied by Limited Review Reports, plus a press release and investor presentation. Given the full-length content (over 142K characters) and likely inclusion of detailed financial statements and analysis, this constitutes a substantive interim/quarterly report rather than merely an earnings snippet or simple notice. Therefore, it should be classified as an Interim/Quarterly Report (IR). 9M 2025
2026-01-28 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.